Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815592 | 1.00 | LPL (0.41) | LPLLIPGSNCAALDH1A1HSD17B10 | |
| SCHEMBL138769 | 0.88 | SNCA (0.42) | LPLLIPGSNCAALDH1A1HSD17B10 | |
| SCHEMBL12502237 | 0.83 | PRMT5 (0.40) | SNCACA1CA2CA9 | |
| SCHEMBL15579103 | 0.75 | AAK1 (0.36) | LPLLIPGSNCA | |
| SCHEMBL29642080 | 0.74 | CLK1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL723057 | 0.74 | CLK1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL489516 | 0.74 | HSD17B10 (0.49) | LPLLIPGSNCAALDH1A1HSD17B10 | |
| SCHEMBL20357 | 0.73 | LPL (0.44) | LPLLIPGSNCAEGFRCA1 | |
| SCHEMBL25290602 | 0.73 | LPL (0.37) | LPLLIPGSNCAEGFR | |
| SCHEMBL18228061 | 0.73 | SNCA (0.43) | LPLLIPGSNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4631941-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025077856-A1 | TRICYCLIC-CARBONYL-NITROGEN HETEROCYCLIC DERIVATIVES AND USE THEREOF | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2025-04-17 | — | — | WO | disclosed |
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | INNOVO THERAPEUTICS INC. (KR) | 2025-04-03 | — | — | US | disclosed |
| EP-4461726-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | Innovo Therapeutics Inc. (KR) | 2024-11-13 | — | — | EP | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024059559-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4263520-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2023-10-25 | — | — | EP | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022063140-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AS HPK1 MODULATOR AND METHODS USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | CASP1, CASP8, CASP2 | LPL 2337/4885LIPG 2901/4885SNCA 3434/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885SNCA 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.